scholarly journals Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes

2020 ◽  
Vol 10 (8) ◽  
Author(s):  
Thuy Thi Nguyen ◽  
Guillaume Gapihan ◽  
Pauline Tetu ◽  
Frédéric Pamoukdjian ◽  
Morad El Bouchtaoui ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Lymph Nodes ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Increased Risk

scholarly journals Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes

Oncotarget ◽  
2017 ◽  
Vol 8 (23) ◽  
pp. 37332-37341 ◽  
Author(s):  
Elise Furet ◽  
Morad El Bouchtaoui ◽  
Jean-Paul Feugeas ◽  
Catherine Miquel ◽  
Christophe Leboeuf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Lymph Nodes ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Increased Risk ◽  
P16 Expression

scholarly journals Increased Risk of Brain Metastases Among Patients with Melanoma and PROM2 Expression in Metastatic Lymph Nodes

2020 ◽  
Author(s):  
Thuy Thi Nguyen ◽  
Guillaume Gapihan ◽  
Pauline Tetu ◽  
Frédéric Pamoukdjian ◽  
Morad El Bouchtaoui ◽  
...  
Keyword(s):  
Lymph Node ◽  
Brain Metastases ◽  
Lymph Nodes ◽  
Metastatic Melanoma ◽  
Metastatic Lymph Nodes ◽  
Transcriptomic Data ◽  
Risk Of Death ◽  
Metastatic Lymph ◽  
Increased Risk ◽  
Melanoma Brain Metastases

Abstract Background: Melanoma brain metastases are the main cause of specific death among patients with metastatic melanoma. The biology of melanoma brain metastases remains largely to be deciphered, as there have been only a few genomic studies on brain metastatic samples. In this study, melanoma metastatic lymph nodes were used with the aim to identify biomarkers associated with the occurrence of brain metastases. Methods: Fifty-one patients with melanoma lymph node metastasis and a median follow-up of 48 months were included in the development cohort. Transcriptomic data were obtained from these metastatic lymph nodes and patients who developed brain metastases and those who did not were compared. Recommendations for tumour marker prognostic studies (REMARK recommendations) were followed.Results: From transcriptomic data, we identified PROM2 which was significantly overexpressed in metastatic lymph nodes of patients who developed brain metastases compared to those who did not. Using immunohistochemistry with two different anti-PROM2 antibodies, a PROM2 score was developed for metastatic lymph nodes. Using a cut-off of 5, a PROM2 mean score ≥5 was significantly associated with an increased risk of brain metastases and an increased hazard risk of death by 4.These results were confirmed in an internal validation cohort of 50 additional patients with melanoma lymph node metastases.Conclusions: In this study, we identified PROM2 expression as a biomarker predictive of the occurrence of distant metastases, particularly brain metastases, among patients with stage III melanoma. Our findings open new perspectives to validate PROM2 as a useful biomarker for clinical trials in the adjuvant setting, and as a potential biotarget for the treatment of metastatic melanoma.

Differentiation of Hyperplastic from Metastatic Lymph Nodes Using a Lymph Node Specific MR Contrast Agent Gadofluorine M

2006 ◽  
Vol 55 (2) ◽  
pp. 183 ◽  
Author(s):  
Joo Hee Cha ◽  
Woo Kyung Moon ◽  
Jung Eun Cheon ◽  
Young Hwan Koh ◽  
Eun Hye Lee ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Nodes ◽  
Contrast Agent ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Gadofluorine M

ENT private eye for unknown primary metastatic lymph nodes

ORL ro ◽  
2019 ◽  
Vol 1 (42) ◽  
pp. 20
Author(s):  
Daniela Vrînceanu ◽  
Mihai Dumitru ◽  
Adriana Nica
Keyword(s):  
Lymph Nodes ◽  
Unknown Primary ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Private Eye

scholarly journals Apparent diffusion coefficient cannot discriminate metastatic and non-metastatic lymph nodes in rectal cancer: a meta-analysis

2021 ◽  
Author(s):  
Alexey Surov ◽  
Hans-Jonas Meyer ◽  
Maciej Pech ◽  
Maciej Powerski ◽  
Jasan Omari ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Diffusion Coefficient ◽  
Apparent Diffusion Coefficient ◽  
Lymph Nodes ◽  
Meta Analysis ◽  
Adc Value ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Apparent Diffusion ◽  
Adc Values

Abstract Background Our aim was to provide data regarding use of diffusion-weighted imaging (DWI) for distinguishing metastatic and non-metastatic lymph nodes (LN) in rectal cancer. Methods MEDLINE library, EMBASE, and SCOPUS database were screened for associations between DWI and metastatic and non-metastatic LN in rectal cancer up to February 2021. Overall, 9 studies were included into the analysis. Number, mean value, and standard deviation of DWI parameters including apparent diffusion coefficient (ADC) values of metastatic and non-metastatic LN were extracted from the literature. The methodological quality of the studies was investigated according to the QUADAS-2 assessment. The meta-analysis was undertaken by using RevMan 5.3 software. DerSimonian, and Laird random-effects models with inverse-variance weights were used to account the heterogeneity between the studies. Mean DWI values including 95% confidence intervals were calculated for metastatic and non-metastatic LN. Results ADC values were reported for 1376 LN, 623 (45.3%) metastatic LN, and 754 (54.7%) non-metastatic LN. The calculated mean ADC value (× 10−3 mm2/s) of metastatic LN was 1.05, 95%CI (0.94, 1.15). The calculated mean ADC value of the non-metastatic LN was 1.17, 95%CI (1.01, 1.33). The calculated sensitivity and specificity were 0.81, 95%CI (0.74, 0.89) and 0.67, 95%CI (0.54, 0.79). Conclusion No reliable ADC threshold can be recommended for distinguishing of metastatic and non-metastatic LN in rectal cancer.

Sign in / Sign up

Export Citation Format

Share Document